Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
Safety and Efficacy of Ivermectin for the Prevention and Treatment of COVID-19: A Double-Blinded Randomized Placebo-Controlled Study
Angkasekwinai et al., Antibiotics, doi:10.3390/antibiotics11060796
12 Jun 2022    Source   PDF   Share   Tweet
Low-risk RCT in Thailand with zero mortality, reporting no significant differences with the addition of ivermectin to favipiravir treatment, however the study as reported does not make sense as detailed below.
All participants were suspected of having COVID-19 and authors assigned 536 PCR- at baseline to a “prevention” study where the only outcome tested was cases. However 62% of these patients were already symptomatic at baseline. Since PCR has a high false negative rate in the first few days, patients may already have COVID-19. It doesn’t make sense to study prevention of cases with already symptomatic patients - studying progression and clinical outcomes would make sense, however authors report only case results. The reported time to PCR+ is also not informative because patients were instructed to do an antigen test only if there were new symptoms (followed by a PCR test).
For both “prevention” and treatment, authors note:
“All participant without evaluable outcomes and drop-out participant were considered as having a poor outcome”, and “…assumed all participants who withdraw or do not take the study drug, and those in the prevention study who do not perform the second NP swab, have a poor outcome.”
This makes no sense, participants that recover quickly are more likely to drop out.
Notably, 100% of the 4 ivermectin patients that did not receive the treatment (which may be because they dropped out) were reported as hospitalized (compared to 2% overall). Authors do not report how many patients dropped out or did not have evaluable outcomes.
We are unable to find protocol registration. The study protocol published with the paper unusually uses past tense in a few places, e.g., “290 patients … were needed”, “The ITT population comprised…”, and “applied a worst-case scenario”, as if it was written after the study. The study protocol file metadata indicates creation June 2022 by Pakpoom Phoompoung. The supplementary figure file shows creation April 2022 by Noppasit Musiwiraphat (not a listed author).
Treatment and placebo were labeled as A and B, meaning any indication of treatment assignment results in a total loss of blinding (e.g., if an investigator observes typical treatment side effects, blinding is lost).
The same hospital has an ivermectin vs. HCQ trial which was registered, was due for completion November 2021, but has not reported results [clinicaltrials.gov].
Dyspnea was ~2x more prevalent in the ivermectin group (9.2% vs. 4.7%), suggesting incomparable groups for serious outcomes.
Studies show that favipiravir is effective, limiting the benefit of additional treatments.
Authors have not responded to a request for the data.
Angkasekwinai et al., 12 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Thailand, peer-reviewed, mean age 38.4, 9 authors, study period August 2021 - November 2021, dosage 400μg/kg days 1-3, 400-600µg/kg.
Contact: nasikarn@gmail.com (corresponding author), pinyo.rat@mahidol.ac.th, methee.cha@mahidol.ac.th, pakpoom.pho@mahidol.ac.th, pornpan.koo@mahidol.ac.th, walaiporn.wan@mahidol.ac.th, visanu.tha@mahidol.ac.th, sorawit.cha@mahidol.ac.th, varalak.sri@mahidol.ac.th, nasikarn.ang@mahidol.ac.th.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit